A detailed history of Primecap Management CO transactions in Guardant Health, Inc. stock. As of the latest transaction made, Primecap Management CO holds 66,176 shares of GH stock, worth $2.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
66,176
Previous 119,976 44.84%
Holding current value
$2.33 Million
Previous $3.25 Million 57.94%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$17.13 - $26.91 $921,594 - $1.45 Million
-53,800 Reduced 44.84%
66,176 $1.37 Million
Q3 2023

Nov 13, 2023

SELL
$25.8 - $39.97 $77,400 - $119,910
-3,000 Reduced 2.44%
119,976 $3.56 Million
Q2 2023

Aug 11, 2023

SELL
$20.94 - $38.01 $1.22 Million - $2.21 Million
-58,068 Reduced 32.07%
122,976 $4.4 Million
Q1 2023

May 15, 2023

SELL
$22.92 - $33.76 $481,320 - $708,960
-21,000 Reduced 10.39%
181,044 $4.24 Million
Q4 2022

Feb 13, 2023

SELL
$25.44 - $59.78 $686,880 - $1.61 Million
-27,000 Reduced 11.79%
202,044 $5.5 Million
Q2 2022

Aug 11, 2022

BUY
$28.82 - $77.35 $618,938 - $1.66 Million
21,476 Added 10.35%
229,044 $9.24 Million
Q1 2022

May 11, 2022

BUY
$48.25 - $100.49 $526,697 - $1.1 Million
10,916 Added 5.55%
207,568 $13.7 Million
Q3 2021

Nov 12, 2021

BUY
$98.77 - $132.17 $5.5 Million - $7.36 Million
55,700 Added 39.52%
196,652 $24.6 Million
Q1 2021

May 14, 2021

BUY
$127.04 - $179.1 $1.64 Million - $2.31 Million
12,900 Added 10.07%
140,952 $21.5 Million
Q4 2020

Feb 08, 2021

BUY
$99.96 - $135.93 $12.5 Million - $16.9 Million
124,602 Added 3611.65%
128,052 $16.5 Million
Q3 2020

Nov 13, 2020

BUY
$80.32 - $111.8 $277,104 - $385,710
3,450 New
3,450 $386,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.61B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Primecap Management CO Portfolio

Follow Primecap Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Primecap Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Primecap Management CO with notifications on news.